Zoetis (NYSE:ZTS) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Zoetis (NYSE:ZTS) announced its earnings results on Thursday. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03, Zacks reports. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis updated its FY 2025 guidance to 6.000-6.100 EPS.

Zoetis Trading Down 6.5 %

Shares of ZTS traded down $11.35 during mid-day trading on Thursday, reaching $162.53. The company’s stock had a trading volume of 8,218,539 shares, compared to its average volume of 2,816,460. The stock has a market cap of $73.33 billion, a PE ratio of 30.49, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis has a 52 week low of $144.80 and a 52 week high of $200.53. The company’s fifty day moving average price is $169.08 and its two-hundred day moving average price is $179.08.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.23%. Zoetis’s payout ratio is 37.59%.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have commented on ZTS. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. Piper Sandler lowered their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus reduced their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Morgan Stanley reduced their price objective on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $214.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.